Opendata, web and dolomites

HypoCyclo SIGNED

Multifunctional Polymeric Cyclodextrin Nanocarriers As Novel Triple-Negative Breast Cancer Treatment: A Versatile Photo-Chemotherapy Bypassing Hypoxic Conditions

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HypoCyclo project word cloud

Explore the words cloud of the HypoCyclo project. It provides you a very rough idea of what is the project "HypoCyclo" about.

assays    cells    ros    demanding    respectively    antitumor    cancers    cyd    tnbc    synthesis    breast    endowed    encapsulate    pdt    biological    green    binding    mixed    load    generate    keep    therapies    insolubility    decorated    2d    subtype    tumours    technological    feasible    alternative    optics    nps    standard    foresees    pcx    paclitaxel    compromises    multimodal    survival    light    completely    hypocyclo    option    solid    tested    worldwide    drug    independent    synthetic    solubilize    models    presenting    collaborating    cyclodextrin    efficacy    situ    ora    cancer    lasers    nanoparticles    successful    agents    source    loaded    fiber    give    covalent    protocols    industrial    therapeutic    supervisor    population    combination    3d    water    ps    guaranteeing    therapy    upgrade    photodynamic    interstitial    thanks    release    20    training    tissue    profile    envisage    reactive    outcome    polymer    limited    tailor    unibo    represented    biocompatible    seeking    triple    sme    innovative    treatment    agent    researcher    releasing    cyclolab    complete    poor    negative    polymeric    species    optimal    photosensitizer    female    vitro    bc    polymers    decoration    er    hypoxia    aggressive    oxygen    operative    options    chemotherapy   

Project "HypoCyclo" data sheet

The following table provides information about the project.

Coordinator
CONSIGLIO NAZIONALE DELLE RICERCHE 

Organization address
address: PIAZZALE ALDO MORO 7
city: ROMA
postcode: 185
website: www.cnr.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 257˙209 €
 EC max contribution 257˙209 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-CAR
 Starting year 2020
 Duration (year-month-day) from 2020-09-01   to  2023-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CONSIGLIO NAZIONALE DELLE RICERCHE IT (ROMA) coordinator 257˙209.00

Map

 Project objective

Among all breast cancers (BC) affecting female population worldwide, 20% is represented by Triple Negative Breast Cancer (TNBC), an aggressive subtype with very limited therapeutic options and poor survival. Seeking for innovative TNBC therapies, HypoCyclo aims at the optimal combination of chemotherapy and photodynamic therapy (PDT). We envisage novel, tailored cyclodextrin (CyD)-based polymeric nanoparticles (NPs) able to load “known” therapeutic agents and decorated with a photosensitizer as well as an Oxygen-Releasing Agent. HypoCyclo focuses on the very effective drug paclitaxel (PCX) presenting several treatment problems like water insolubility. Biocompatible, novel CyD polymers are expected to solubilize and encapsulate through non-covalent binding the drug of choice in order to implement PCX chemotherapy with PDT, through the decoration with a PS able to generate antitumor reactive oxygen species (ROS) in situ. Indeed, PDT has become a very challenging yet feasible option thanks to the technological advances in lasers and fiber-optics allowing interstitial and intra-operative light delivery for the treatment of solid tumours, including BC. Finally, as hypoxia in BC tissue compromises standard chemotherapy and PDT, we will tailor our NPs with an ORA able to release oxygen in cells, enabling an alternative ROS source. The PCX loaded NPs will be completely characterized and tested in 2D and 3D TNBC models. Our goal is to keep the synthetic protocols simple, low-cost and green to facilitate industrial upgrade of the loaded multimodal NPs endowed with improved in vitro efficacy. Two partners, the SME Cyclolab and UNIBO, both already collaborating with the supervisor, will give the necessary support in mixed-CyD polymer synthesis and in the biological assays, respectively, guaranteeing a successful outcome. The project foresees a demanding training program for ER that will help him to become an independent researcher with a complete profile.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYPOCYCLO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HYPOCYCLO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MemoryAggregates (2020)

Mechanism of Whi3 Aggregation and its Age-dependent Malfunction

Read More  

5G-ACE (2019)

Beyond 5G: 3D Network Modelling for THz-based Ultra-Fast Small Cells

Read More  

CODer (2020)

The molecular basis and genetic control of local gene co-expression and its impact in human disease

Read More